secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liminatus Pharma, Inc. (LIMN)
CIK:        0001971387
Form:       8-K12B
Filed at:   2025-04-30T23:59:59+00:00
Accession:  0001104659-25-042489
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Liminatus Pharma completes business combination with Iris Acquisition Corp; trades as LIMN
--------------------------------------------------------------------------------

- Combined company Liminatus Pharma, Inc. begins trading on Nasdaq under LIMN and LIMNW on May 1, 2025.
- Liminatus develops anti-CD47 monoclonal antibody IBA101 for advanced solid cancers including non-small cell lung cancer.
- Leadership: CEO Chris Kim, CFO Scott Dam, CSO Byong C. Yoo.
- Business Combination approved at Iris stockholders meeting on March 4, 2025.
- Advisors: Holland & Knight for Iris, Loeb & Loeb for Liminatus, Raymond James.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971387/000110465925042489/0001104659-25-042489-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971387/000110465925042489/tm2513514d1_8k12b.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-042489

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer